Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) was up 4.5% during trading on Thursday . The stock traded as high as C$22.75 and last traded at C$21.52. Approximately 2,458,116 shares changed hands during mid-day trading, an increase of 69% from the average daily volume of 1,455,874 shares. The stock had previously closed at C$22.53.
Several equities research analysts recently commented on VRX shares. Royal Bank Of Canada reiterated a “sector perform” rating and issued a C$23.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Wednesday, November 8th. TD Securities upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective on the stock in a research report on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and a consensus target price of C$22.50.
In other news, Director Schutter Richard Urbain De bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was purchased at an average price of C$14.33 per share, with a total value of C$143,300.00.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2017/12/07/valeant-pharmaceuticals-international-vrx-trading-up-4-5.html.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.